JW (Cayman) Therapeutics Co. Ltd (HKG:2126)
Hong Kong · Delayed Price · Currency is HKD 2.420
-0.050 (-2.02%)
Apr 17, 2026, 4:08 PM HKT
HKG:2126 Revenue
In the year 2025, JW (Cayman) Therapeutics Co. had annual revenue of 283.65M CNY with 79.28% growth. JW (Cayman) Therapeutics Co. had revenue of 177.31M in the half year ending December 31, 2025, with 105.89% growth.
Revenue
283.65M CNY
Revenue Growth
+79.28%
P/S Ratio
3.11
Revenue / Employee
903.35K CNY
Employees
314
Market Cap
981.65M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 283.65M | 125.44M | 79.28% |
| Dec 31, 2024 | 158.22M | -15.64M | -8.99% |
| Dec 31, 2023 | 173.86M | 28.15M | 19.32% |
| Dec 31, 2022 | 145.70M | 114.91M | 373.10% |
| Dec 31, 2021 | 30.80M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 586.21M |
| 3D Medicines | 396.26M |
| Wuhan YZY Biopharma | 85.20M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| CANbridge Pharmaceuticals | 55.62M |
| Shanghai Bio-heart Biological Technology | 50.00M |
| Brii Biosciences | 39.56M |
| Kintor Pharmaceutical | 36.37M |